These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39611607)
1. Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study. Palazzuoli A; Pirrotta F; Cartocci A; Delcuratolo E; Dini FL; Correale M; Dattilo G; Masarone D; Scelsi L; Ghio S; Tocchetti CG; Mercurio V; Brunetti ND; Nodari S; Barillà F; Ambrosio G; Carluccio E Ther Adv Cardiovasc Dis; 2024; 18():17539447241285136. PubMed ID: 39611607 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor-neprilysin inhibition and improved ventricular-arterial coupling in heart failure with reduced ejection fraction. Stegmann T; Parentin L; Schirmer SH; Lavall P; Hagendorff A; Laufs U; Lavall D Am J Physiol Heart Circ Physiol; 2024 Dec; 327(6):H1477-H1489. PubMed ID: 39453422 [TBL] [Abstract][Full Text] [Related]
3. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. Lu H; Claggett BL; Packer M; Lam CSP; Swedberg K; Rouleau J; Zile MR; Lefkowitz M; Desai AS; Jhund P; McMurray JJV; Solomon SD; Vaduganathan M JAMA Cardiol; 2024 Nov; 9(11):1047-1052. PubMed ID: 39210725 [TBL] [Abstract][Full Text] [Related]
4. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Shaddy R; Burch M; Kantor PF; Solar-Yohay S; Garito T; Zhang S; Kocun M; Mao C; Cilliers A; Wang X; Canter C; Rossano J; Wallis G; Menteer J; Daou L; Kusa J; Tokel K; Dilber D; Xu Z; Xiao T; Halnon N; Daly KP; Bock MJ; Zuckerman W; Singh TP; Chakrabarti M; Levitas A; Senni M; Grutter G; Kim GB; Song J; Lee HD; Chen CK; Sanchez-de-Toledo J; Law Y; Wanitkun S; Cui Y; Anjos R; Mese T; Bonnet D; Circulation; 2024 Nov; 150(22):1756-1766. PubMed ID: 39319469 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials. Butt JH; McMurray JJV; Claggett BL; Jhund PS; Neuen BL; McCausland FR; Desai AS; Lam CSP; Pitt B; Pfeffer MA; Packer M; Beldhuis IE; Voors AA; Zannad F; Heerspink HJL; Solomon SD; Vaduganathan M Circulation; 2024 Dec; 150(23):1858-1868. PubMed ID: 39217458 [TBL] [Abstract][Full Text] [Related]
6. Effect of optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study. Zheng A; Adam R; Peebles C; Harden S; Shambrook J; Abbas A; Vedwan K; Adam G; Haydock P; Cowburn P; Young C; Long J; Walkden M; Smith S; Greenwood E; Olden P; Flett A Open Heart; 2024 Dec; 11(2):. PubMed ID: 39622578 [TBL] [Abstract][Full Text] [Related]
8. Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial. Fudim M; Cyr DD; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sharma K; Claggett BL; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E; Mentz RJ; J Card Fail; 2024 Dec; 30(12):1568-1577. PubMed ID: 38802053 [TBL] [Abstract][Full Text] [Related]
9. Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study. Mebazaa A; Davison BA; Biegus J; Edwards C; Murtagh G; Varounis C; Hayrapetyan H; Sisakian H; Ter-Grigoryan VR; Takagi K; Novosadova M; Ponikowski P; Cotter G Eur J Heart Fail; 2024 Jul; 26(7):1507-1517. PubMed ID: 38721803 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Initiating Sacubitril-Valsartan With Spironolactone During Hospitalization for Acute Decompensated Heart Failure. Levine AR; Sasiela K; Baker M J Pharm Pract; 2025 Feb; 38(1):43-51. PubMed ID: 39024019 [No Abstract] [Full Text] [Related]
12. The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better. Loria F; Mone P; Rispoli A; Di Fonzo R; Masarone D; Mancusi C; Correale M; Vitullo A; Granatiero M; Mazzeo P; Mercurio V; Fiore F; Di Sarro E; Falco L; Izzo C; Campanile A; Virtuoso N; Stabile E; Bonanno S; Dattilo G; Tocchetti CG; Santulli G; Vecchione C; Ciccarelli M; Visco V Cardiovasc Diabetol; 2024 Nov; 23(1):423. PubMed ID: 39578847 [TBL] [Abstract][Full Text] [Related]
13. Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease. Saka Y; Takahashi H; Naruse T; Watanabe Y Clin Exp Nephrol; 2024 Dec; 28(12):1327-1331. PubMed ID: 39361183 [TBL] [Abstract][Full Text] [Related]
14. Synbiotics, prebiotics and probiotics for people with chronic kidney disease. Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of beta-blocker use by N-terminal pro-brain natriuretic peptide level in acute heart failure patients. Kim SJ; Ann SH; Park GM; Kim YG; Park S; Lee SG ESC Heart Fail; 2024 Dec; 11(6):3842-3853. PubMed ID: 39015043 [TBL] [Abstract][Full Text] [Related]
16. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
17. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
18. Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF. Shoji S; Cyr DD; Hernandez AF; Velazquez EJ; Ward JH; Williamson KM; Sarwat S; Starling RC; Desai AS; Zieroth S; Solomon SD; Mentz RJ Am Heart J; 2025 Feb; 280():70-78. PubMed ID: 39505123 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial. Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Kitamura T; Guo W Circ J; 2018 Sep; 82(10):2575-2583. PubMed ID: 30047502 [TBL] [Abstract][Full Text] [Related]